Me at My Best” in the Year of the Rat: SBK 2020 Annual Gala Report

Time flies, and in the blink of an eye, SBK has proudly marked its fifth anniversary. Over the past five years, we have steadfastly upheld our core values of “Empowering Better Health Through Inclusive Care and Support”, embraced the spirit of “innovation, collaboration, progress, and gratitude”, and remained true to our mission: to develop affordable, high-quality medicines that treat disease and save lives. With unwavering dedication to our founding vision and a commitment to scientific excellence, we achieved remarkable progress in 2019.

On January 18, 2020, the entire SBK team, together with our sister company, Sichuan Renfu Group · Chengdu Huabeikang Pharmaceutical Co., Ltd., gathered at the Chengdu Mengtongquan Ecological Hotel for the 2020 New Year Celebration & 2019 Annual Review Conference.

During the conference, Dr. Cen Guodong, CEO of the company, delivered a comprehensive report on SBK’s 2019 performance. He announced that the company’s independently developed Class 1.1 innovative drug, SBK002, had received clinical trial acceptance. Following productive technical discussions with the Center for Drug Evaluation of the National Medical Products Administration, clinical trial approval is expected in the near future. In addition, two other new drug candidates have successfully completed preclinical studies and are projected to enter the application phase by mid-2020. The company’s financing plan has been largely finalized and is set to officially launch after the Chinese New Year. Partnership agreements have also made significant progress, and in 2020, SBK looks forward to working hand-in-hand with like-minded collaborators to achieve mutual growth.

Following Dr. Cen’s remarks, Mr. Yang Maoting, the company’s General Manager, expressed heartfelt appreciation to all employees for their efforts. He also shared his expectations and outlined key priorities for SBK in the year ahead. We extend our heartfelt thanks to everyone for your dedication and unwavering commitment to SBK. The year 2020 marks a pivotal chapter in SBK’s journey—a time of accelerated growth and opportunity. We hope each member of our team will continue to unlock their full potential and help shape a brighter future through wisdom, passion, and perseverance.

In 2019, we rose to challenges and laid a strong foundation. Like a seed nurtured for four years, SBK has now taken root and begun to sprout. In 2020, we will continue to cultivate this growth—nurturing it to blossom, bear fruit, and turn what once seemed impossible into reality.

Looking ahead, we will take pride in being part of SBK—in the breakthroughs we achieve and the contributions we make to global health!

Stay true to our mission. Forge ahead with purpose. Me at My Best in the Year of the Rat!

From all of us at Chengdu Shibeikang Biomedical Technology Co., Ltd., we wish you:A Happy New Year! Good Health! Joyful Moments with Your Loved Ones!